Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7083106> ?p ?o }
Showing triples 1 to 62 of
62
with 100 triples per page.
- Q7083106 subject Q7334142.
- Q7083106 subject Q7486806.
- Q7083106 subject Q8248726.
- Q7083106 subject Q8431759.
- Q7083106 subject Q8707914.
- Q7083106 subject Q8955377.
- Q7083106 subject Q9672646.
- Q7083106 abstract "Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA. The FDA approval is in for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy.".
- Q7083106 atcPrefix "L01".
- Q7083106 atcSuffix "XX46".
- Q7083106 casNumber "763113-22-0".
- Q7083106 chEBI "83766".
- Q7083106 fdaUniiCode "WOH1JD9AR8".
- Q7083106 iupacName "4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl) -4-fluorophenyl]methyl(2H)phthalazin-1-one".
- Q7083106 pubchem "23725625".
- Q7083106 thumbnail Olaparib.svg?width=300.
- Q7083106 wikiPageWikiLink Q1139164.
- Q7083106 wikiPageWikiLink Q130146.
- Q7083106 wikiPageWikiLink Q172341.
- Q7083106 wikiPageWikiLink Q17853272.
- Q7083106 wikiPageWikiLink Q181257.
- Q7083106 wikiPageWikiLink Q204711.
- Q7083106 wikiPageWikiLink Q210538.
- Q7083106 wikiPageWikiLink Q2112244.
- Q7083106 wikiPageWikiLink Q2198549.
- Q7083106 wikiPageWikiLink Q227339.
- Q7083106 wikiPageWikiLink Q254327.
- Q7083106 wikiPageWikiLink Q29496.
- Q7083106 wikiPageWikiLink Q3907241.
- Q7083106 wikiPageWikiLink Q4836333.
- Q7083106 wikiPageWikiLink Q492646.
- Q7083106 wikiPageWikiLink Q5445.
- Q7083106 wikiPageWikiLink Q6151460.
- Q7083106 wikiPageWikiLink Q7118227.
- Q7083106 wikiPageWikiLink Q7180990.
- Q7083106 wikiPageWikiLink Q7202320.
- Q7083106 wikiPageWikiLink Q731938.
- Q7083106 wikiPageWikiLink Q7334142.
- Q7083106 wikiPageWikiLink Q7486806.
- Q7083106 wikiPageWikiLink Q8047.
- Q7083106 wikiPageWikiLink Q8248726.
- Q7083106 wikiPageWikiLink Q8431759.
- Q7083106 wikiPageWikiLink Q8707914.
- Q7083106 wikiPageWikiLink Q886518.
- Q7083106 wikiPageWikiLink Q8955377.
- Q7083106 wikiPageWikiLink Q9672646.
- Q7083106 wikiPageWikiLink Q9690.
- Q7083106 atcPrefix "L01".
- Q7083106 atcSuffix "XX46".
- Q7083106 casNumber "763113".
- Q7083106 chebi "83766".
- Q7083106 iupacName "4".
- Q7083106 pubchem "23725625".
- Q7083106 unii "WOH1JD9AR8".
- Q7083106 type ChemicalSubstance.
- Q7083106 type Drug.
- Q7083106 type ChemicalObject.
- Q7083106 type Thing.
- Q7083106 type Q8386.
- Q7083106 comment "Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA.".
- Q7083106 label "Olaparib".
- Q7083106 depiction Olaparib.svg.